Search Results
Jul 30, 2026, 16:05 ET Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
growth in the markets we serve, including the proteomics market; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to successfully integrate SomaLogic, Inc. and
More news about: Illumina, Inc.
Jul 30, 2026, 16:00 ET Coveo Reports First Quarter Fiscal 2027 Financial Results
Adjusted Product Gross Profit, and Adjusted Professional Services Gross Profit (collectively referred to as our "Adjusted Gross Profit Measures"); (iii) Adjusted Gross Margin, Adjusted Product Gross Margin, and Adjusted Professional Services Gross Margin (collectively referred to as our "Adjusted Gross
More news about: Coveo Solutions Inc.
Jul 30, 2026, 16:00 ET Coveo Reports First Quarter Fiscal 2027 Financial Results
Adjusted Product Gross Profit, and Adjusted Professional Services Gross Profit (collectively referred to as our "Adjusted Gross Profit Measures"); (iii) Adjusted Gross Margin, Adjusted Product Gross Margin, and Adjusted Professional Services Gross Margin (collectively referred to as our "Adjusted Gross
More news about: Coveo Solutions Inc.
Jul 30, 2026, 12:45 ET AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC
d'accident vasculaire cérébral lors d'un essai clinique de Phase III, établissant ainsi une nouvelle référence en matière de réduction du risque cardiovasculaire.Recommandation fondée sur l'essai clinique mondial de Phase III VESALIUS-CV, étude de référence portant sur plus de 12 000 patients
More news about: Amgen
Jul 30, 2026, 11:19 ET REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026
Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly
More news about: SueWallSt.com
Jul 30, 2026, 10:31 ET Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
mechanism helps suppress cytokine production and modulate immune cell activity, thereby reducing inflammation. ABX464 is currently undergoing Phase III clinical evaluation for the treatment of patients with moderately to severely active ulcerative colitis.Merck's Tulisokibart (MK-7240) is
More news about: DelveInsight Business Research, LLP
Jul 30, 2026, 10:07 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
Begin: February 2026 ReassessmentWhen Grail disclosed on February 19, 2026, that the "primary endpoint of statistically significant Stage III-IV reduction was not observed," the analyst consensus fractured overnight. Coverage that had been anchored to confidence in the three-year trial design
More news about: SueWallSt.com
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
joining the class action]On April 29, 2026, during during Regeneron's first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival."On
More news about: Pomerantz LLP
Jul 30, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against BitGo Holdings, Inc. and Certain Officers - BTGO
Defendants' statements regarding, inter alia, BitGo's financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and/or failed
More news about: Pomerantz LLP
Jul 30, 2026, 09:06 ET New Designation Offers Expertise in Donor-Advised Funds
George Nichols III, president and CEO of The American College of Financial Services. "The DAFCP™ will help advisors stand out as specialists in a fast-growing
More news about: The American College of Financial Services
Jul 30, 2026, 09:00 ET Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
entire drug discovery value chain, nominating 31 preclinical candidates in six years and advancing an AI-discovered and AI-designed medicine into Phase III. The DDD Benchmark converts that real-world experience into a rigorous, standardized yardstick that the whole field can use. As we advance toward pharmaceutical
More news about: Insilico Medicine
Jul 30, 2026, 09:00 ET Multigenerational Travel Can Boost Healthy Aging, Social Engagement, and Economic Growth
https://doi.org/10.1080/13683500.2016.1157142[iii] Collinson, C., & Cho, H. (2025, October 8). Retirement Throughout the Ages: The American Middle Class, 25th Annual Transamerica Retirement
More news about: Transamerica Institute
Jul 30, 2026, 09:00 ET CULLEN/FROST REPORTS SECOND QUARTER RESULTS
of 2026 were 13.95 percent, 14.38 percent and 15.74 percent, respectively, and continue to be in excess of well-capitalized levels and exceed Basel III minimum requirements.During the second quarter, our base of customer households continued to grow. Total households, including consumer and
More news about: Cullen/Frost Bankers, Inc.
Jul 30, 2026, 08:15 ET POZYTYWNA OPINIA CHMP OTWIERA DROGĘ DO SZERSZEGO STOSOWANIA LEKU REPATHA® FIRMY AMGEN PRZED WYSTĄPIENIEM PIERWSZEGO ZAWAŁU SERCA LUB UDARU MÓZGU
którego w badaniu klinicznym fazy III wykazano istotne zmniejszenie ryzyka pierwszego zawału serca i udaru mózgu, ustanawiając tym samym nowy standard ograniczania ryzyka sercowo-naczyniowegoZalecenie oparto na przełomowym, globalnym badaniu fazy III VESALIUS-Cardiovascular, obejmującym
More news about: Amgen
Jul 30, 2026, 08:00 ET Century Casinos Announces Dates of Second Quarter 2026 Earnings Release and Conference Call
includes the Century Casinos & Hotels in Cape Girardeau and Caruthersville, Missouri, and in Cripple Creek and Central City, Colorado; (iii) US West includes the Nugget Casino Resort in Reno-Sparks, Nevada; (iv) Canada includes Century Casino & Hotel in Edmonton,
More news about: Century Casinos, Inc.
Jul 30, 2026, 07:57 ET EVERSANA Selected by Innovacell as Commercialization Partner to Advance Novel Cell Therapy ICEF15 in the United States
regenerating muscle tissue via the local administration of a patient's own skeletal myoblasts. ICEF15 is currently undergoing a multi-regional Phase III clinical trial (Fidelia Study) in the United States, 11 European countries, and Japan. To date, Innovacell has completed multiple clinical trials in
More news about: EVERSANA
Jul 30, 2026, 07:45 ET Hot Chili Quarterly Report - Period Ending 30 June 2026
81PORFIADA III100% Frontera SpA
More news about: Hot Chili Limited
Jul 30, 2026, 07:30 ET JLL Reports Financial Results for Second-Quarter 2026
Capital Markets Services and (iii) Advisory fees, within Investment Management.The company defines "Advisory" revenue (previously referred to as "Transactional") as (i) Portfolio Services and Other, within Real Estate Management Services, (ii) Leasing Advisory, (iii) Investment Sales, Debt/Equity
More news about: JLL-IR
Jul 30, 2026, 07:30 ET Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
are at significant risk for STIs based on a uniquely large dataset reflecting the nation's heterogenous population," said co-author Damian P. Alagia III, MD, a board-certified obstetrician/gynecologist and Senior Medical Director, Women's Health, Quest Diagnostics. "STIs can lead to serious reproductive
More news about: Quest Diagnostics
Jul 30, 2026, 07:30 ET First Ever, Data-Driven Outcome-based Analysis and Ranking of Privately Held Global Defense Tech Companies Released
imagined."The lists were developed by Future Union using primary source data to include FAR-based contracts, OTAs, SBIR/STTR awards, DPA Title III funding, and global procurement announcements, which were then combined through a scoring system weighted by government-contract demand (55%), independent
More news about: Future Union
Jul 30, 2026, 07:00 ET AAON Increases Board Size and Appoints Robert L. Buttermore III, and Patrick J. Jermain as Independent Directors
high-performing, energy-efficient HVAC solutions that bring long-term value to customers and owners, today announced the appointment of Robert L. Buttermore III, and Patrick J. Jermain to its Board of Directors, effective July 28, 2026. AAON also announced that Mr. Buttermore will serve on the Compensation Committee
More news about: AAON
Jul 30, 2026, 07:00 ET International Paper Reports Second Quarter 2026 Results
earnings; (ii) our ability to successfully integrate and realize anticipated synergies, cost savings and profit opportunities from corporate transactions; (iii) risks associated with our strategic business decisions including facility closures, business exits, operational changes, corporate restructurings and
More news about: International Paper
Jul 30, 2026, 07:00 ET Terex Reports Second Quarter 2026 Results
same tools that management uses to budget, make operating and strategic decisions, and evaluate our core operating performance across periods, and (iii) otherwise provide supplemental information that may be useful to investors in evaluating our financial results. We do not, nor do we suggest that investors,
More news about: Terex Corporation
Jul 30, 2026, 06:55 ET QUANTA SERVICES REPORTS SECOND QUARTER 2026 RESULTS
are impacted by Quanta's acquisition activities and investments in integral unconsolidated affiliates, and therefore can vary from period to period; (iii) acquisition and integration costs vary from period to period depending on the level and complexity of Quanta's acquisition activity; (iv) change in
More news about: Quanta Services, Inc.
Jul 30, 2026, 06:50 ET Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
results, including global economic and market conditions on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and
More news about: Labcorp Holdings Inc